-
Mashup Score: 5
Eli Lilly won FDA approval to market its diabetes drug Mounjaro for obesity. That drug, which will be sold as Zepbound, introduces stiff competition for Novo Nordisk, maker of Wegovy.
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Osimertinib Combo Under Priority Review for EGFR+ Locally Advanced/Metastatic NSCLC - 7 month(s) ago
The FDA has granted priority view to osimertinib plus chemotherapy based on data from the phase 3 FLAURA2 trial.
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Warehouses Are Calling In the Gig Workers - 7 month(s) ago
Logistics operators are giving workers more flexibility as competition for labor from Uber, Instacart and other app-driven companies heats up.
Source: www.wsj.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0Psychiatric News Brief - 7 month(s) ago
Alexa Flash Briefings from Psychiatric News
Source: alexapn.libsyn.comCategories: Latest Headlines, PsychiatryTweet
-
Mashup Score: 1UC San Diego and Mount Sinai Receive $8.5M NIH Award for Data Integration Hub – San Diego Biotechnology Network - 7 month(s) ago
Researchers at UC San Diego and the Icahn School of Medicine at Mount Sinai have been awarded an $8.5 million grant to create a data integration hub aimed at accelerating novel therapeutics and cures for diseases within initiatives supported by the NIH Common … Click here to view original
Source: sdbn.orgCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0
In a single-center retrospective analysis, the median progression-free survival among patients with multiple myeloma treated with teclistamab was 4.7 months.
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Social media traffic to top news sites craters - 7 month(s) ago
Website business models that depended on clicks from social media are now broken.
Source: www.axios.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0
In a single-center retrospective analysis, the median progression-free survival among patients with multiple myeloma treated with teclistamab was 4.7 months.
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Covid News Updates - 8 month(s) ago
News about COVID-19 including shortages, pandemic modeling, viability and susceptibility. Learn how physicians are coping.
Source: www.todayshospitalist.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 2Ford supplier invests $790M to build 3 Tennessee plants - 9 month(s) ago
Magna International will produce key parts for Ford’s second-generation electric truck, and is the first company to join the automaker’s supplier park.
Source: www.supplychaindive.comCategories: Healthcare Professionals, Latest HeadlinesTweet
#News Eli Lilly gets FDA approval to sell Mounjaro as obesity drug called Zepbound. https://t.co/GWq6GSd7Zr